高迁移率族蛋白B1与乳腺癌

国际肿瘤学杂志››2020,Vol. 47››Issue (5): 297-300.doi:10.3760/cma.j.cn371439-20200414-00022

张艳强¹, 章阳¹(), 李春华², 张典平³, 刘保国¹, 彭显更¹

¹山东省聊城市人民医院乳腺甲状腺外科,betway必威登陆网址 (betway.com )252000
²山东省聊城市东昌府区妇幼保健院手术麻醉科 252000
³山东省莘县第三人民医院神经内科 252427

收稿日期:2020-04-14修回日期:2020-04-18出版日期:2020-05-08发布日期:2020-07-02
通讯作者:章阳 E-mail:zhangyang5366@163.com

High mobility group protein B1 and breast cancer

Zhang Yanqiang¹, Zhang Yang¹(), Li Chunhua², Zhang Dianping³, Liu Baoguo¹, Peng Xiangeng¹

¹Department of Breast and Thyroid Surgery, Liaocheng People's Hospital of Shandong Province, Shandong First Medical University & Shandong Academy of Medical Sciences, Liaocheng 252000, China;
²Department of Surgical Anesthesia, Dongchangfu Maternal and Child Health Hospital of Liaocheng, Shandong Province, Liaocheng 252000, China
³Department of Neurology, Shenxian Third People's Hospital of Shandong Province, Shenxian 252427, China

Received:2020-04-14Revised:2020-04-18Online:2020-05-08Published:2020-07-02
Contact:Zhang Yang E-mail:zhangyang5366@163.com

摘要/Abstract

摘要：

高迁移率族蛋白B1(HMGB1)是一类广泛存在于细胞内的核蛋白,当机体受到应激刺激时从细胞中释放或分泌,在细胞的存活/死亡途径中起关键作用。HMGB1具有巨大的生物学功能,是炎性疾病和肿瘤等重大疾病的主要调节因子。HMGB1与肿瘤细胞的增殖、分化、迁移、凋亡及耐药关系密切。随着对HMGB1研究的不断深入,发现其在乳腺癌的发生、发展、转移及耐药中扮演重要角色。结合HMGB1研究现状,探讨其在乳腺癌中的表达,可为临床探索新的治疗方案提供依据。

关键词:HMGB1蛋白质,乳腺肿瘤,肿瘤转移,抗药性,肿瘤

Abstract:

High mobility group protein B1 (HMGB1) is a kind of nuclear protein widely existing in cells, which is released or secreted from cells by stress in the body and plays a key role in the survival or death pathways of cells. HMGB1 has a huge biological function and is the main regulator of major diseases such as inflammatory diseases and tumors. HMGB1 is closely related to the proliferation, differentiation, migration, apoptosis and drug resistance of tumor cells. With the continuous deepening of research on HMGB1, it is found that HMGB1 plays an important role in the occurrence, development, metastasis and drug resistance of breast cancer. Combined with the research status of HMGB1, the expression of HMGB1 in breast cancer is discussed to provide a new therapeutic scheme for clinical treatment.

Key words:HMGB1 protein,Breast neoplasms,Neoplasm metastasis,Drug resistance,neoplasm

张艳强, 章阳, 李春华, 张典平, 刘保国, 彭显更. 高迁移率族蛋白B1与乳腺癌[J]. 国际肿瘤学杂志, 2020, 47(5): 297-300.

Zhang Yanqiang, Zhang Yang, Li Chunhua, Zhang Dianping, Liu Baoguo, Peng Xiangeng. High mobility group protein B1 and breast cancer[J]. Journal of International Oncology, 2020, 47(5): 297-300.

参考文献26

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi:10.3322/caac.21492pmid:30207593
[2]	Van Rooijen JM, Qiu SQ, Timmer-Bosscha H, et al. Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2-positive breast cancer[J]. Eur J Cancer, 2018,103:52-60. DOI: 10.1016/j.ejca.2018.08.001. doi:10.1016/j.ejca.2018.08.001pmid:30208359
[3]	Xu Y, Chen Z, Zhang G, et al. HMGB1 overexpression correlates with poor prognosis in early-stage squamous cervical cancer[J]. Tumour Biol, 2015,36(11):9039-9047. DOI: 10.1007/s13277-015-3624-7. doi:10.1007/s13277-015-3624-7pmid:26084608
[4]	Reeves R. High mobility group (HMG) proteins: modulators of chromatin structure and DNA repair in mammalian cells[J]. DNA Repair (Amst), 2015,36:122-136. DOI: 10.1016/j.dnarep.2015.09.015. doi:10.1016/j.dnarep.2015.09.015
[5]	Taniguchi N, Kawakami Y, Maruyama I, et al. HMGB proteins and arthritis[J]. Hum Cell, 2018,31(1):1-9. DOI: 10.1007/s13577-017-0182-x. doi:10.1007/s13577-017-0182-xpmid:28916968
[6]	Yang R, Zou X, Tenhunen J, et al. HMGB1 and extracellular histones significantly contribute to systemic inflammation and multiple organ failure in acute liver failure[J]. Mediators Inflamm, 2017,2017:5928078. DOI: 10.1155/2017/5928078. doi:10.1155/2017/5928078pmid:28694564
[7]	张静娇, 邓春青. 与疾病相关的HMGB1基因多态性研究进展[J]. 国际生物医学工程杂志, 2019,42(4):357-361. DOI: 10.3760/cma.j.issn.1673-4181.2019.04.015.
[8]	Yun CW, Lee SH. The roles of autophagy in cancer[J]. Int J Mol Sci, 2018, 19(11). pii: E3466. DOI: 10.3390/ijms19113466.
[9]	Kumai T, Celis E, Rodriguez PC. Editorial: A matter of survival: HMGB1 regulates autophagy in tumor MDSC[J]. J Leukoc Biol, 2016,100(3):447-449. DOI: 10.1189/jlb.3CE0216-091R. doi:10.1189/jlb.3CE0216-091Rpmid:27587376
[10]	Su Z, Ni P, She P, et al. Bio-HMGB1 from breast cancer contri-butes to M-MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC-like cells[J]. Cancer Immunol Immunother, 2017,66(3):391-401. DOI: 10.1007/s00262-016-1942-2. doi:10.1007/s00262-016-1942-2pmid:27987020
[11]	Zhao Y, Wu T, Shao S, et al. Phenotype, development, and biological function of myeloid-derived suppressor cells[J]. Oncoimmunology, 2016,5(2):e1004983. DOI: 10.1080/2162402x.2015.1004983. doi:10.1080/2162402X.2015.1004983pmid:27057424
[12]	Wang H, Zou C, Zhao W, et al. Juglone eliminates MDSCs accumulation and enhances antitumor immunity[J]. Int Immunopharmacol, 2019,73:118-127. DOI: 10.1016/j.intimp.2019.04.058. doi:10.1016/j.intimp.2019.04.058pmid:31085459
[13]	Wan W, Cao L, Khanabdali R, et al. The emerging role of HMGB1 in neuropathic pain: a potential therapeutic target for neuroinflammation[J]. J Immunol Res, 2016,2016:6430423. DOI: 10.1155/2016/6430423. doi:10.1155/2016/6430423pmid:27294160
[14]	Bhat AA, Uppada S, Achkar IW, et al. Tight junction proteins and signaling pathways in cancer and inflammation: a functional crosstalk[J]. Front Physiol, 2018,9:1942. DOI: 10.3389/fphys.2018.01942. doi:10.3389/fphys.2018.01942pmid:30728783
[15]	Ying S, Xiao X, Chen T, et al. PPAR ligands function as suppressors that target biological actions of HMGB1[J]. PPAR Res, 2016,2016:2612743. DOI: 10.1155/2016/2612743. doi:10.1155/2016/2612743pmid:27563308
[16]	王超群, 黄必飞, 王艳, 等. 乳腺癌中高迁移率族蛋白B1蛋白表达及其临床病理意义[J]. 中华病理学杂志, 2020,49(1):57-61. DOI: 10.3760/cma.j.issn.0529-5807.2020.01.011.
[17]	Sharma AK, Sharma VR, Gupta GK, et al. Advanced glycation end products (AGEs), glutathione and breast cancer: factors, mechanism and therapeutic interventions[J]. Curr Drug Metab, 2019,20(1):65-71. DOI: 10.2174/1389200219666180912104342. doi:10.2174/1389200219666180912104342pmid:30207227
[18]	Xiang L, Semenza GL. Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy[J]. Adv Cancer Res, 2019,141:175-212. DOI: 10.1016/bs.acr.2018.11.001. doi:10.1016/bs.acr.2018.11.001pmid:30691683
[19]	Wang F, Sheng JF, Cai L, et al. The telomerase and alternative lengthening of telomeres mechanisms regulate laryngeal cancer cell apoptosis via the PI3K/Akt pathway[J]. ORL J Otorhinolaryngol Relat Spec, 2018,80(5-6):227-237. DOI: 10.1159/000489461. doi:10.1159/000489461pmid:30212832
[20]	Shi Y, Zhang W, Ye Y, et al. Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway[J]. Cancer Biol Med, 2018,15(3):314-321. DOI: 10.20892/j.issn.2095-3941.2017.0188. doi:10.20892/j.issn.2095-3941.2017.0188pmid:30197799
[21]	Choi AH, O'leary MP, Lu J, et al. Endogenous Akt activity promotes virus entry and predicts efficacy of novel chimeric orthopoxvi-rus in triple-negative breast cancer[J]. Mol Ther Oncolytics, 2018,9:22-29. DOI: 10.1016/j.omto.2018.04.001. doi:10.1016/j.omto.2018.04.001pmid:29988465
[22]	Sharifi S, Barar J, Hejazi MS, et al. Doxorubicin changes Bax/Bcl-xL ratio, caspase-8 and 9 in breast cancer cells[J]. Adv Pharm Bull, 2015,5(3):351-359. DOI: 10.15171/apb.2015.049. doi:10.15171/apb.2015.049pmid:26504757
[23]	Xu T, Jiang L, Wang Z. The progression of HMGB1-induced autophagy in cancer biology[J]. Onco Targets Ther, 2019,12:365-377. DOI: 10.2147/ott.S185876. doi:10.2147/OTT.S185876pmid:30643434
[24]	Wang N, Yang B, Muhetaer G, et al. XIAOPI formula promotes breast cancer chemosensitivity via inhibiting CXCL1/HMGB1-mediated autophagy[J]. Biomed Pharmacother, 2019,120:109519. DOI: 10.1016/j.biopha.2019.109519. doi:10.1016/j.biopha.2019.109519pmid:31629951
[25]	Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction[J]. Pharmacol Ther, 2017,172:34-49. DOI: 10.1016/j.pharmthera.2016.11.012. doi:10.1016/j.pharmthera.2016.11.012pmid:27916656
[26]	Sun Q, Liu T, Yuan Y, et al. MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1[J]. Int J Cancer, 2015,136(5):1003-1012. DOI: 10.1002/ijc.29065. doi:10.1002/ijc.29065pmid:25044403